Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $2,272 | $8,699 | $40,518 | $17,874 |
| Operating expenses: | ||||
| Research and development | 51,293 | 43,469 | 98,733 | 84,091 |
| General and administrative | 24,781 | 17,989 | 46,884 | 36,346 |
| Total operating expenses | 76,074 | 61,458 | 145,617 | 120,437 |
| Loss from operations | (73,802) | (52,759) | (105,099) | (102,563) |
| Other income, net: | ||||
| Interest income | 4,722 | 2,372 | 10,013 | 5,247 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's G&A?
- Wave Life Sciences (WVE) reported G&A of $24.78M in Q2 2026.
- How has Wave Life Sciences's G&A changed year-over-year?
- Wave Life Sciences's G&A increased by 37.8% year-over-year, from $17.99M to $24.78M.
- What is the long-term trend for Wave Life Sciences's G&A?
- Over 4 years (2021 to 2025), Wave Life Sciences's G&A has grown at a 13.1% compound annual growth rate (CAGR), from $46.11M to $75.33M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Wave Life Sciences's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude